Clinical Drug Investigation

, Volume 26, Issue 8, pp 459–467 | Cite as

Serum Levels and Possible Haemodynamic Effects following Anorectal Application of an Ointment Containing Nifedipine and Lignocaine

A Study in Healthy Volunteers
  • Pasquale Perrotti
  • Lucia Grumetto
  • Francesco Barbato
  • Carmine Antropoli
Original Research Article


Objectives: This study aimed to assess whether topical anorectal application of an ointment containing nifedipine (0.3% w/w) and lignocaine (lidocaine) [1.5% w/w] to healthy adult volunteers gives rise to pharmacologically relevant serum levels of the active ingredients and has any haemodynamic effects or side effects.

Methods: A dose of 3g of the ointment was circumferentially applied inside the anus to 12 healthy volunteers every 12 hours for 7 days. Blood samples were collected at 0, 30, 60, 240, 480 and 720 minutes after the first application; in addition, blood samples were collected at days 1 and 7 after multiple applications. Serum concentrations of nifedipine, its main metabolites and lignocaine were determined by a new high-performance liquid chromatography method established for the purpose of the study. Volunteers’ blood pressure, heart rate, ECG status and laboratory parameters were monitored throughout the study.

Results: Topical application of the ointment to healthy volunteers did not produce therapeutically significant serum levels of the active ingredients and/or their active metabolites. Indeed, Chromatographic signals of the active ingredients and/or nifedipine metabolites were only sporadically observed, below the quantification limits for the method, and consistent with therapeutically negligible concentrations. No serious local or systemic adverse events were observed throughout the study, and no subjects developed arrhythmias or significant ECG changes. Neither blood pressure nor mean heart rate varied significantly after application of a single dose. After multiple doses, mean systolic and diastolic blood pressure remained close to baseline levels for the duration of the study. The mean heart rate after multiple doses was about 5% below baseline level at days 1 and 7; however, these differences were not statistically significant.

Conclusion: This study demonstrates the safety of topical anorectal application of an ointment containing nifedipine (0.3% w/w) and lignocaine (1.5% w/w) to healthy volunteers.


Nifedipine Lignocaine Anal Fissure Internal Anal Sphincter Chronic Anal Fissure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Nifedipine and lignocaine (lidocaine) hydrochloride were kindly donated by New.Fa.Dem srl, Giugliano, Italy. No sources of funding were used to assist in the preparation of this article. The authors have no potential conflicts of interest directly relevant to the contents of this study.


  1. 1.
    Lund JN, Scholefield H. Aetiology and treatment of anal fissure. Br J Surg 1996; 83: 1335–44PubMedCrossRefGoogle Scholar
  2. 2.
    Farouk R, Duthie GS, MacGregor AB, et al. Sustained internal sphincter hypertonia in patients with chronic anal fissure. Dis Colon Rectum 1994; 37: 424–9PubMedCrossRefGoogle Scholar
  3. 3.
    Schouten WR, Briel JW, Auwerda JJ, et al. Ischaemic nature of anal fissure. Br J Surg 1996; 83: 63–5PubMedCrossRefGoogle Scholar
  4. 4.
    Nelson RL. Operative procedures for fissure in ano. iCochrane Database Syst Rev 2001; (3): CD002199Google Scholar
  5. 5.
    Jonas M, Scholefield JH. Anal fissure. Gastroenterol Clin North Am 2001; 30: 167–81PubMedCrossRefGoogle Scholar
  6. 6.
    Khubchandani IT, Reed JF. Sequelae of internal sphincterotomy for chronic anal fissure in ano. Br J Surg 1989; 76: 431–4PubMedCrossRefGoogle Scholar
  7. 7.
    Nyam DCNK, Pemberton JH. Long-term results of lateral internal sphincterotomy for chronic anal fissure with particula reference to incidence of fecal incontinence. Dis Colon Rectum 1999; 42: 1306–10PubMedCrossRefGoogle Scholar
  8. 8.
    Jost WH. One hundred cases of anal fissure treated with botulin toxin: early and long-term results. Dis Colon Rectum 1997; 40: 1029–32PubMedCrossRefGoogle Scholar
  9. 9.
    Maria G, Cassetta E, Gui D, et al. A comparison of botulinum toxin and saline for the treatment of chronic anal fissure. N Engl J Med 1998; 338: 217–20PubMedCrossRefGoogle Scholar
  10. 10.
    Minguez M, Herreros B, Espi A, et al. Long-term follow-up (42 months) of chronic anal fissure after healing with botulinum toxin. Gastroenterology 2002; 123: 112–7PubMedCrossRefGoogle Scholar
  11. 11.
    Jost WH, Schanne S, Militz H, et al. Perianal thrombosis following injection therapy into external anal sphincter using botulin toxin [letter]. Dis Colon Rectum 1995; 38: 781PubMedCrossRefGoogle Scholar
  12. 12.
    Schouten WR, Briel JW, Boerma MO, et al. Pathophysiological aspects and clinical outcome of intra-anal application of isosorbide dinitrate in patients with chronic anal fissure. Gut 1996; 39: 465–9PubMedCrossRefGoogle Scholar
  13. 13.
    Lund JN, Scholefield JH. A randomized, prospective, double-blind, placebo-controlled trial of glyceryl trinitrate ointment in treatment of anal fissure. Lancet 1997; 349: 11–4PubMedCrossRefGoogle Scholar
  14. 14.
    Bacher H, Mischinger HJ, Werkgartner G, et al. Local nitroglycerin for treatment of anal fissures: an alternative to lateral sphincterotomy? Dis Colon Rectum 1997; 40: 840–5PubMedCrossRefGoogle Scholar
  15. 15.
    Hyman NH, Cataldo PA. Nitroglycerin ointment for anal fissures: effective treatment or just a headache? Dis Colon Rectum 1999; 42: 383–5PubMedCrossRefGoogle Scholar
  16. 16.
    Antropoli C, Perrotti P, Rubino M, et al. Nifedipine for local use in conservative treatment of anal fissures: preliminary results of a multicenter study. Dis Colon Rectum 1999; 42: 1011–5PubMedCrossRefGoogle Scholar
  17. 17.
    Cook TA, Humphreys MM, Mortensen NJ. Oral nifedipine reduces resting anal pressure and heals chronic anal fissure. Br J Surg 1999; 86: 1269–73PubMedCrossRefGoogle Scholar
  18. 18.
    Carapeti EA, Kamm MA, Phillips RKS. Topical diltiazem and bethanechol decrease anal sphincter pressure and heal anal fissures without side effects. Dis Colon Rectum 2000; 43: 1359–62PubMedCrossRefGoogle Scholar
  19. 19.
    Jonas M, Neal KR, Abercrombie JF, et al. A randomized trial of oral vs topical diltiazem for chronic anal fissures. Dis Colon Rectum 2001; 44: 1074–8PubMedCrossRefGoogle Scholar
  20. 20.
    Jonard P, Essamri B. Diltiazem and internal anal sphincter [letter]. Lancet 1987; I: 754CrossRefGoogle Scholar
  21. 21.
    Altomare DF, Rinaldi M, Milito G, et al. Glyceryl trinitrate for chronic anal fissure: healing or headache? Results of a multi-center, randomized, placebo-controlled, double-blind trial. Dis Colon Rectum 2000; 43: 174–9PubMedCrossRefGoogle Scholar
  22. 22.
    Richard CS, Gregoire R, Plewes EA, et al. Internal sphincterotomy is superior to topical nitroglycerin in the treatment of chronic anal fissure: results of a randomized, controlled trial by the Canadian Colorectal Surgical Trials Group. Dis Colon Rectum 2000; 43: 1048–57PubMedCrossRefGoogle Scholar
  23. 23.
    Carapeti EA, Kamm MA, McDonald PJ, et al. Randomised controlled trial shows that glyceryl trinitrate heals anal fissures, higher doses are not more effective, and there is a high recurrence rate. Gut 1999; 44: 727–30PubMedCrossRefGoogle Scholar
  24. 24.
    Knight JS, Birks M, Farouk R. Topical diltiazem ointment in the treatment of chronic anal fissure. Br J Surg 2001; 88: 553–6PubMedCrossRefGoogle Scholar
  25. 25.
    Kocher HM, Steward M, Leather AJ, et al. Randomized clinical trial assessing the side-effects of glyceryl trinitrate and diltiazem hydrochloride in the treatment of chronic anal fissure. Br J Surg 2002; 89: 413–7PubMedCrossRefGoogle Scholar
  26. 26.
    Ezri T, Susmallian S. Topical nifedipine vs topical glyceryl trinitrate for treatment of chronic anal fissure. Dis Colon Rectum 2003; 46: 805–8PubMedCrossRefGoogle Scholar
  27. 27.
    Chrysos E, Xynos E, Tzovaras G, et al. Effect of nifedipine on rectoanal motility. Dis Colon Rectum 1996; 39: 212–6PubMedCrossRefGoogle Scholar
  28. 28.
    Cook TA, Brading AF, Mortensen NJ. Effects of nifedipine on anorectal smooth muscle in vitro. Dis Colon Rectum 1999; 42: 782–7PubMedCrossRefGoogle Scholar
  29. 29.
    Cook TA, Brading AF, Mortensen NJ. Differences in contractile properties of anorectal smooth muscle and the effects of calcium channel blockade. Br J Surg 1999; 86: 70–5PubMedCrossRefGoogle Scholar
  30. 30.
    Perrotti P, Antropoli C, Noschese G, et al. Topical nifedipine for conservative treatment of acute hemorrhoidal thrombosis. Colorectal Dis 2000; 2: 18–21CrossRefGoogle Scholar
  31. 31.
    Perrotti P, Antropoli C, Molino D, et al. Conservative treatment of acute thrombosed external hemorrhoids with topical nifedipine. Dis Colon Rectum 2001; 44: 405–9PubMedCrossRefGoogle Scholar
  32. 32.
    Perrotti P, Bove A, Antropoli C, et al. Topical nifedipine with lidocaine ointment vs. active control for treatment of chronic anal fissure: results of a prospective, randomized, double-blind study. Dis Colon Rectum 2002; 45: 1468–75PubMedCrossRefGoogle Scholar
  33. 33.
    Jensen SL. Treatment of first episodes of acute anal fissure: prospective randomised study of lignocaine ointment versus hydrocortisone ointment or warm sitz baths plus bran. BMJ (Clin Res Ed) 1986; 292: 1167–9CrossRefGoogle Scholar
  34. 34.
    McDonald P, Driscoll AM, Nicholls RJ. The anal dilator in the conservative management of acute anal fissures. Br J Surg 1983; 70: 25–6PubMedCrossRefGoogle Scholar
  35. 35.
    Triggle DJ. Calcium, calcium channels, and calcium channel antagonists. J Physiol Pharmacol 1990; 68: 1474–81CrossRefGoogle Scholar
  36. 36.
    Raemsch KD, Sommer J. Pharmacokinetics and metabolism of nifedipine. Hypertension 1983; 5: 18–24Google Scholar
  37. 37.
    Traube M, Hongo M, McAllister Jr RG, et al. Correlation of plasma levels of nifedipine and cardiovascular effects after sublingual dosing in normal subjects. J Clin Pharmacol 1985; 25: 125–9PubMedGoogle Scholar
  38. 38.
    Kurosawa S, Kurosawa N, Owada E, et al. Rectal administration of nifedipine: hemodynamic effects and pharmacokinetics in hypertensives. J Int Med Res 1987; 15: 121–7PubMedGoogle Scholar
  39. 39.
    Kleinbloesem CH, van Brummelen P, van de Linde JA, et al. Nifedipine: kinetics and dynamics in healthy subjects. Clin Pharmacol Ther 1984; 35: 742–9PubMedCrossRefGoogle Scholar
  40. 40.
    Kleinbloesem CH, van Harten J, de Leede LG, et al. Nifedipine kinetics and dynamics during rectal infusion to steady state with an osmotic system. Clin Pharmacol Ther 1984; 36: 396–4PubMedCrossRefGoogle Scholar
  41. 41.
    Covino BG. Toxicity of local anesthetic agents. Acta Anaesthesiol Belg 1988; 39(3 Suppl. 2): 159–64PubMedGoogle Scholar
  42. 42.
    Strichartz G. Molecular mechanisms of nerve block by local anesthetics. Anesthesiology 1976; 45: 421–41PubMedCrossRefGoogle Scholar
  43. 43.
    Tucker GT. Clinical pharmacokinetics of local anesthetics. Clin Pharmacokinet 1979; 4: 241–78PubMedCrossRefGoogle Scholar
  44. 44.
    Barbato F, Cappello B, Grumetto L, et al. Analysis of calcium blocking dihydropyridines by high performance liquid chromatography. Farmaco 1993; 48(3): 417–26Google Scholar
  45. 45.
    Barbato F, Grumetto L, Morrica P. Analysis of calcium blocking dihydropyridines and their degradation products by gas chromatography. Farmaco 1993; 49(7–8): 461–6Google Scholar
  46. 46.
    Hardman JG, Limbird LE, Molinoff PB, et al. Goodman & Gilman’s The pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996; 1195: 1754–65Google Scholar
  47. 47.
    Tonsuwannont W, Praisontarangkul OA, Manorot M, et al. Pharmacokinetics of oral lidocaine and nifedipine in patients with liver cirrhosis. J Med Assoc Thai 1996; 79: 309–19PubMedGoogle Scholar
  48. 48.
    Brown AC, Sumfest JM, Rozwadowski JV. Histopathology of the internal anal sphincter in chronic anal fissure. Dis Colon Rectum 1989; 32: 680–3PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  • Pasquale Perrotti
    • 1
  • Lucia Grumetto
    • 2
  • Francesco Barbato
    • 2
  • Carmine Antropoli
    • 1
  1. 1.Department of Gastroenterology, Chirurgia Gastroenterologica‘A. Cardarelli’ HospitalNaplesItaly
  2. 2.Department of Pharmaceutical and Toxicological ChemistryUniversity Federico IINaplesItaly

Personalised recommendations